CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.
CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.
To compare a stable dose of salmeterol/fluticasone propionate with a variable dose of
 formoterol/budesonide where the dose is adjusted according to a physician-guided
 self-management plan
A randomised, double-blind, double-dummy, 52-week, parallel group study of a standard dosing
 regimen with salmeterol/fluticasone propionate combination 50/250mcg bid (via the
 DISKUS/ACCUHALER inhaler) versus a symptom-driven variable dosing regimen with
 formoterol/budesonide combination 6/200mcg (via a breath-actuated dry powder reservoir
 inhaler)in adults asthmatics
Inclusion Criteria:

 -  Documented clinical history of asthma

 -  Forced expiratory volume in 1 second between 60% and 90% of predicted

 -  Using an inhaled corticosteroid (ICS)at a dose equivalent to 200 to 500 mcg daily of
 beclomethasone (BDP)or equivalent combined with a long-acting beta-2-agonist or an ICS
 alone at a dose equivalent to >500 to 1000mcg daily of BDP daily

 Exclusion Criteria:

 -  Lower respiratory tract infection within 1 month of study entry

 -  Use of systemic corticosteroids within 1 month of study entry

 -  Smoking history of 10 pack years or more Changes in regular asthma therapy within 12
 weeks of study entry

 -  Any significant disorder that in the investigator's opinion might put the patient at
 risk or influence the study outcomes